AI Article Synopsis
Article Abstract
A retrospective analysis was conducted on 20 D(-) liver transplant (LT) recipients transfused with D(+) RBCs perioperatively and screened for RBC antibodies between 2 and 6 months later. None developed anti-D detectable by the indirect antiglobulin test. Two patients produced weak anti-D that reacted only with papain-treated RBCs at 10 and 11 days without any sign of immune haemolysis. Antibodies became quickly undetectable. These data suggest an unusual pattern of alloimmunization in LT recipients with rapid, weak and transient antibody response and support the safety of transfusing D(+) RBCs in most of D(-) patients during LT surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/vox.12392 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibody dynamics in dogs submitted to different canine visceral leishmaniasis treatment protocols.
Rev Bras Parasitol Vet
January 2025
Programa de Pós-graduação em Medicina Veterinária, Laboratório de Doenças Parasitárias, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria - UFSM, Santa Maria, RS, Brasil.
This study evaluated dynamics of antibodies in dogs treated for canine visceral leishmaniasis (CVL). Twenty-one dogs naturally infected by Leishmania spp. were grouped based on the treatment protocol: G1 (n=4) received allopurinol; G2 (n=10) allopurinol with miltefosine; and G3 (n=7) allopurinol, miltefosine and Leish-Tec® vaccine.
View Article and Find Full Text PDFInhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy.
Sci Transl Med
January 2025
Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder. Antiamyloid antibody treatments modestly slow disease progression in mild dementia due to AD. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays an important role in disease onset and progression.
View Article and Find Full Text PDFThe Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.
Protein Cell
January 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Despite their therapeutic potential, the use of ADCs faces significant challenges, including off/on-target toxicity and resistance development. This review examines the current landscape of ADC development, focusing on the critical aspects of target selection and antibody engineering.
View Article and Find Full Text PDFCarbon-dot pequi-nut in the development of immunosensor to detect pathogenic bacteria.
Braz J Microbiol
January 2025
Centro de Ciências, Universidade Estadual do Ceará, CCT, Fortaleza, Brazil.
Carbon dots in biosensing have advanced significantly, adding improvements to different detection techniques. In this study, an amperometric immunosensor for Salmonella Thyphimurium was designed using antibodies labeled with carbon dots (Cdots) from pequi almond (Caryocar brasiliensis). Cdots were synthesized by pyrolysis and characterized by FTIR, UV/fluorescence, electrochemistry, zeta potential, and transmission electron microscopy (TEM).
View Article and Find Full Text PDFEffect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass.
Osteoporos Int
January 2025
Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Unlabelled: We investigated the efficacy of romosozumab in premenopausal women with low bone mass. Romosozumab substantially increased bone mineral density and trabecular bone score in these women, aligning with its proven therapeutic benefits for postmenopausal osteoporosis.
Purpose: Romosozumab, an anti-sclerostin antibody, is a promising anabolic agent that increases bone formation and decreases bone resorption.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!